gurufocus.comSEP 162 min read$TAK

Takeda Pharmaceutical (TAK) Insider Sale: Chief Transformation O

Takeda Pharmaceutical's (TAK) Chief Transformation Officer sold 34,535 shares on 2026-09-14, continuing a year-long insider selling trend. The company's shares trade at $18.54, with a market cap of $59.72 billion. GuruFocus values the stock at $14.16, indicating it is significantly overvalued. Some institutional investors have increased holdings despite insider sales.

Original reporting

gurufocus.com

Published Sep 16, 2026, 4:19 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 16, 2026, 4:49 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$TAK

Bearish

medium confidence

Mentioned

$TAK

Relevance

4/10

AlphAI data visualization · based on gurufocus.com

Decision brief

The 30-second read

$TAKBearishLow

Why it matters

The disclosed Form 4 filing is the first public report of this specific sale, providing new data for traders.

Market read

Insider net selling signals potential downside, but mixed guru activity and overvaluation nuance the view.

What to watch

Valuation premium to GF Value and pipeline prospects may offset insider selling concerns.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑14

Background

Takeda trades as ADR TAK on US exchanges; insider activity is regularly tracked by investors.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TAKBearishMedium confidence

Context

Chief Transformation Officer Lauren Duprey sold 34,535 shares of Takeda on 2026-09-14, increasing her total insider sales to 82,121 shares.

Expected impact

Potential modest short-term price dip as insiders reduce exposure.

Evidence & confidence

Insider sales by a senior executive are a bearish signal, but the size relative to market cap is modest.

Market effects

Sector

Limited; reflects broader insider sentiment in the pharma sector.

Regional

Minor impact on Japan‑focused pharma stocks.

Global

Low; isolated to Takeda ADR.

Counterpoint

What could challenge this read

Guru investors are adding to positions, indicating confidence despite insider sales.

Key entities

company
Takeda Pharmaceutical Co Ltd
Japanese pharma company listed in the US as ADR TAK.
person
Lauren Duprey
Chief Transformation Officer at Takeda, insider seller.

Read at source ← All news

OCT 6

$TAKMedAI 9/10

Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data

Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.

hcplive.com2 min

OCT 3

$PFEHighAI 9/10

Targeted Drug Duo with Lighter Chemotherapy Delivers 97% Survival in

A phase 2 trial showed a regimen combining brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine achieved 92% complete response and 97% 2-year progression-free survival in early-stage Hodgkin lymphoma. The study, published in Advances in Therapy, involved 154 patients and was funded by Seagen (now Pfizer), Takeda, and Bristol-Myers Squibb.

bioengineer.org3 min

OCT 2

$BIIBMed

CMS's GLOBE Drug Pricing Plan Collapses to $400M in Savings, Leaving a Four-Company Test

CMS's GLOBE drug pricing plan's projected savings dropped from $11.9B to $400M, affecting about four manufacturers, including Biogen, Takeda, and Daiichi Sankyo. The reduction is due to exclusions for GARD participants. The final rule may face legal challenges and has raised concerns about its effectiveness.

finance.biggo.com4 min

SEP 30

$TAKHighAI 9/10

Oveporexton Improves Wakefulness and Cataplexy in Narcolepsy Type 1

Takeda's Oveporexton (Orzeyful) significantly improved wakefulness, daytime sleepiness, and cataplexy in narcolepsy type 1 patients over 12 weeks, according to two phase 3 trials. The FDA approved the drug in August 2026, positioning it as the first therapy addressing orexin deficiency. Adverse events included increased urinary frequency and transient insomnia. Trials showed mean sleep latency improvements of 14.3 to 19.8 minutes with Oveporexton vs. placebo.

ajmc.com3 min

SEP 30

$TAKMedAI 8/10

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Takeda announced Phase 3 trial results showing zasocitinib (TAK-279) demonstrated superior efficacy in treating moderate-to-severe plaque psoriasis compared to deucravacitinib. Key data: 36.5% of patients achieved complete skin clearance (PASI 100) at week 16 vs. 13.9% for deucravacitinib. Zasocitinib also showed durable skin clearance and improvements in itch and quality of life. The drug is under regulatory review for psoriasis treatment.

intelligencer.ca2 min

SEP 22